Evidence map›Paper›PMID 38846982›Full record

ArticleFrontiers in oncology2024

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.

Yuta Hoshi, Tomohiro Enokida, Shingo Tamura, Torahiko Nakashima, Susumu Okano, Takao Fujisawa, Masanobu Sato, Akihisa Wada, Hideki Tanaka, Naohiro Takeshita and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yuta HoshiDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Shingo TamuraDepartment of Medical Oncology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Torahiko NakashimaDepartment of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Susumu OkanoDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Takao FujisawaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Masanobu SatoDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Akihisa WadaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Hideki TanakaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Naohiro TakeshitaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Nobukazu TanakaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Ryutaro OnagaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Takuma KishidaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.
Hideoki UryuDepartment of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Shingo SakashitaDivision of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Takahiro AsakageDepartment of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center East Hospital, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Olfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the recurrent or metastatic (R/M) ONB population remains unclear. Methods: We retrospectively evaluated 11 patients with R/M ONB who received any systemic chemotherapy at two Japanese institutions (National Cancer Center Hospital East and Kyushu Medical Center) between January 2002 and March 2022 and analyzed outcomes by use of anti-PD-1 antibody (nivolumab or pembrolizumab) monotherapy. Results: Of the 11 patients, 6 received ICI (ICI-containing treatment group) and the remaining 5 were treated with systemic therapy but not including ICI (ICI-non-containing treatment group). Overall survival (OS) was significantly longer in the ICI-containing group (median OS: not reached Conclusion: ICI monotherapy appears to be effective and to contribute to prolonged survival in R/M ONB.

Indexed as

anti-PD-1 monotherapyimmune checkpoint inhibitornivolumabolfactory neuroblastomapembrolizumab

Identifiers

PMID38846982
PMCPMC11153745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.